Xenon nears a Q3 2026 NDA with strong Phase 3 epilepsy data and a cash runway to 2029. Click here to read an analysis of XENE ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
GlobalData on MSN
Enrolment concludes in Biohaven’s RISE3 trial for epilepsy
Topline results from RISE3 are expected in H2 2026.
EpilepsyGTx has partnered with ClearPoint Neuro to enable targeted delivery of its lead gene therapy candidate, EPY201, ahead ...
Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies to treat a broad range of rare and ...
EpilepsyGTx, a biotechnology company developing cutting-edge gene therapies to treat refractory epilepsy, and ClearPoint ...
Please provide your email address to receive an email when new articles are posted on . Seizure freedom was observed by 12 months and continued past 48 months of the open-label extension. Long-term ...
Prior to being diagnosed with epilepsy, 5% of people with a type of epilepsy called focal epilepsy had a seizure while driving, according to a new study published in the June 7, 2023, online issue of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results